Semnur Pharmaceuticals Reports $4.3 Million Net Loss in Latest Quarter, Highlights Increased Operating Expenses

Semnur Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $4.3 million for the quarter, compared to a loss of $999,000 in the same period last year. For the first half of 2026, the net loss totaled $8.9 million, a substantial increase from $1.7 million in the first half of 2025. The increase in losses is attributed to heightened operating expenses, which surged to $4.2 million in the second quarter of 2026, up from $999,000 in the prior year, and $8.8 million for the first half of 2026, compared to $1.7 million in 2025.

The company's operating expenses were primarily driven by research and development (R&D) costs, which rose to $1.2 million in the second quarter of 2026 from $502,000 in the same quarter of 2025. This increase reflects ongoing clinical development activities for Semnur's lead product candidate, SP-102, a non-opioid treatment for lumbosacral radicular pain. General and administrative expenses also saw a significant rise, reaching $3 million in the second quarter of 2026, compared to $497,000 in the same period last year, largely due to increased personnel costs and expenses associated with operating as a public company.

In terms of strategic developments, Semnur completed a business combination with Denali Capital Acquisition Corp. on September 22, 2025, which resulted in a name change and the establishment of a new corporate structure. The company has also initiated a second Phase 3 study for SP-102, following the successful completion of a pivotal Phase 3 study in March 2022. The company is focused on expanding its clinical trials and regulatory approvals, which are critical for its growth and market entry.

As of June 30, 2026, Semnur reported total assets of $1.9 million, up from $1.3 million at the end of 2025. However, total liabilities increased significantly to $31.6 million, compared to $22.1 million at the end of the previous year, primarily due to a rise in related party loans. The company’s accumulated deficit also grew to $284.7 million, reflecting its ongoing investment in R&D and operational costs. Semnur's cash and cash equivalents stood at $39,000, raising concerns about its liquidity and ability to fund future operations without additional financing.

Looking ahead, Semnur anticipates continued operating losses as it progresses with its clinical development plans. The company is exploring various financing options, including equity offerings and collaborations, to secure the necessary capital for its operations. Management has expressed concerns about its ability to continue as a going concern, emphasizing the need for additional funding to support its ongoing activities and development of SP-102.